13 November 2019
Event date: 28 November
The Johnson & Johnson Innovation Partnering Office @ Monash (JJIPO@Monash) invites you to a Keynote presentation from Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson.
Dr. Stoffels is a visionary scientist who has changed the lives of millions around the world. He led the development of several breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition. He now spearheads the Johnson & Johnson research and product pipeline by leading teams across the pharmaceutical, medical devices and consumer segments to discover and develop healthcare solutions to address unmet needs.
Following the Keynote presentation Paul will be joined by Adrian Thomas, Vice President, Global Programs Strategy & Evaluation and Cat Oyler, Vice-President Global Public Health, Tuberculosis, Johnson & Johnson Global Public Health for an interactive panel discussing public private partnerships in global public health.
Tickets are limited so please register early to secure your place.
Date: Thursday 28 November 2019
Time : 1.30 pm sharp start – 3.30 pm (includes 30 minutes networking time)
Where: JJIPO@Monash event to be held at – Green Chemical Futures Building, 13 Rainforest Walk, Level 4, Green Chemical Futures Bldg, Clayton, VIC 3800
RSVP : 23 November 2019.
Special Keynote Presentation –
Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer
Johnson & Johnson
Dr. Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world.
Paul spearheads the Johnson & Johnson research and product pipeline by leading teams across all our sectors to set the companywide innovation agenda, discovering and developing transformational healthcare solutions. He also is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company’s global public health strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings.
Dr. Stoffels’ commitment to fuelling innovation and finding the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to foster science and technology through strategic partnerships, licensing and acquisitions. Paul also oversees JJDC, the oldest corporate venture fund in the life science industry.
Previously, in his role as Worldwide Chairman, Pharmaceuticals, Paul led the transformation of the pharmaceutical research and development pipeline for Janssen Pharmaceutical Companies of Johnson & Johnson, driving a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation. Under his leadership, Janssen rejuvenated its pipeline, launching multiple new medicines and making a difference for people all over the world.
Prior to this, Dr. Stoffels held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of several breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition.
Dr. Stoffels studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.
Adrian Thomas, M.D., Vice President, Global Programs Strategy & Evaluation, Global Public Health
Johnson & Johnson
Adrian serves as the Vice-President, Global Programs Strategy & Evaluation with the Johnson & Johnson Global Public Health Organization.
Adrian has a special interest in the fields of public health, commercial and market access strategy, and pharmaceutical policy. He also held numerous roles in market access including Global Head Health Economics & Market Access Medical Devices. He was Global Head of Market Access for Janssen, the pharmaceutical companies of Johnson & Johnson, as well as roles in risk management and drug safety, including Global Head of Benefit Risk Manager and Chief Safety Office for Janssen.
Prior to joining Johnson & Johnson, Adrian held roles in regional medical affairs, drug development and product management for Schering-Plough and Eli Lilly. He is a clinical pharmacologist and vascular physician with experience in clinical trials design and methodology.
Adrian is a Fellow of the Royal Australasian College of Physicians and the College of Medical Administrator’s. He received his Bachelor of Medicine and Bachelor of Surgery degrees from the University of Melbourne in Australia.
Vice-President, Global Public Health, Tuberculosis, Johnson & Johnson Global Public Health
Johnson & Johnson
Cat Oyler serves as Vice President, Global Public Health (GPH), leading the Tuberculosis (TB) Focus Area Strategy Team (FAST) and as a member of the GPH Executive Leadership Team. In this role, Cat leads the enterprise TB FAST to deliver on our aspiration to create a world without tuberculosis through ending mortality from multidrug-resistant tuberculosis (MDR-TB). The TB FAST includes a dedicated cross-functional group of professionals representing marketing, market access, research & development, on-the-ground execution, external affairs and consumer programming.
Cat also serves as executive sponsor for the University workstream for WiSTEM2D (Women in Science Technology Engineering Math Manufacturing and Design). WiSTEM2D is a Johnson & Johnson initiative leveraging external partnerships to harness global communities, academic institutions and NGOs with a goal of building a diverse and healthy workforce for the future.
Cat has a B.A. in Biology from Williams College and a MBA from the UCLA Anderson School of Management.